source
- Dr Bockorny on the Rationale for Targeting CCR8 in Solid TumorsBruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.onclive · 2mo ago↗ source
- Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech, wh…Endpoints · 2mo ago↗ source
- Lilly data point to ‘maintenance’ strategies for GLP-1 weight lossA pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.